Saturday 17 October 2026
Export PETS’s income statement to Excel — free account
PetMed Express, Inc.
PETS Healthcare Pharmaceutical Retailers
PetMed Express, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $179.0 million, down 21.1% from fiscal 2025. In the quarter to June 2026, revenue fell 19.9%, EPS grew 83.0% and free cash flow grew 38.6%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
1.20
0.02
−1.64%
Follow PETS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.26 | 0.36 | 0.27 | 0.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.12) | (7.30) | (10.05) | (5.42) | |
P/B ratio |
1.22 | 2.05 | 1.65 | 1.81 | |
Price to Tangible BV |
1.68 | 3.13 | 2.63 | 3.35 | |
EV/Sales |
0.08 | 0.22 | 0.15 | 0.17 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.90) | (2.42) | (0.93) | (1.20) | |
EV/FCF |
(1.04) | (1.76) | (0.80) | (1.03) | |
Quick Ratio |
0.67 | 0.52 | 0.45 | 0.36 | |
Current Ratio |
1.05 | 0.89 | 0.84 | 0.68 | |
Net Debt/EBITDA |
1.08 | 3.34 | (0.89) | 3.20 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.61 | 1.61 | 1.56 | 1.95 | |
Operating CF/Net income |
0.26 | 0.87 | 1.17 | 1.25 | |
Capex/Depreciation |
0.11 | 0.01 | (0.02) | (0.30) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
41.74% | 43.10% | 40.19% | 37.59% | |
Intangible Assets out of Total Assets |
0.12 | 0.13 | 0.13 | 0.17 | |
Share Based Compensation of Revenue |
0.56% | 0.62% | 0.64% | 0.48% | |
Graham Net Nets |
0.04 | (0.10) | (0.18) | (0.32) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(105.58%) | (97.50%) | (120.61%) | (71.88%) | |
Free Cash Flow Yield |
(29.91%) | (34.09%) | (69.20%) | (66.72%) | |
Revenue per Share |
2.12 | 1.94 | 2.05 | 1.89 | |
Operating CF per Share |
(0.10) | (0.44) | (0.23) | (0.35) | |
Capex per Share |
(0.13) | 0.00 | (0.03) | (0.03) | |
Free Cash Flow per Share |
(0.23) | (0.44) | (0.26) | (0.38) | |
Cash per Share |
1.73 | 1.28 | 1.02 | 0.60 | |
Shareholders Equity per Share |
2.06 | 1.56 | 1.38 | 1.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.06 | 1.56 | 1.38 | 1.06 | |
Free Cash Flow |
(4.80) | (9.18) | (5.46) | (8.33) | |
Working Capital |
2.77 | (6.26) | (8.47) | (12.99) | |
Capital Expenditures |
(2.62) | 0.02 | (0.72) | (0.64) | |
Net Current Asset Value |
2.22 | (6.69) | (8.69) | (13.17) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.00 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.79 | 1.91 | 2.11 | 1.66 | |
Average Payables |
18.04 | 15.62 | 22.24 | 16.17 | |
Average Inventory |
13.93 | 12.00 | 14.91 | 13.41 | |
Average Assets |
123.17 | 116.38 | 114.95 | 86.80 | |
Average Common Equity |
69.74 | 64.47 | 57.03 | 37.26 |
Columns are period end dates